Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tilbroquinol is a halogenated 8-hydroxyquinoline compound with antiprotozoal activity, primarily used for the treatment of intestinal amoebiasis. It is often administered in combination with tiliquinol (as in the product INTETRIX) and has also shown activity against *Vibrio cholerae*. The precise mechanism of action remains unclear, but it is believed to involve chelation of metal ions essential for enzymatic processes within protozoa, thereby disrupting their metabolic functions and DNA synthesis. Tilbroquinol was approved in France, Morocco, and Saudi Arabia; however, it has been withdrawn from markets in France and Saudi Arabia due to hepatotoxicity concerns. In Morocco, its use is restricted to intestinal amoebiasis[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tilbroquinol.